2 choices. Every 2 weeks or once a month. No titration
Repatha® offers your patients the flexibility of a single monthly injection or an injection every 2 weeks.1
Every 2 weeks
Single-use prefilled autoinjector
Consider the SureClick® autoinjector for patients who are comfortable self-injecting with a hand-held device.
How to use Repatha® SureClick®
Download the Instructions for Use.
Once a month
Single-use on-body infusor with prefilled cartridge
The Pushtronex® system securely adheres to the body for hands-free administration while patients perform activities requiring moderate exertion.
After one push of a button, the on-body device does the work.
How to use Repatha® Pushtronex® System
Download the Instructions for Use.
Feel confident your patients can administer Repatha® with either delivery option
*Patients who reported 2 full-dose administrations of Repatha® at weeks 4 and 8. Patients received training from healthcare professionals on how to self-administer.2
†Patients used the Pushtronex® system or 3 autoinjectors for the once-monthly regimen.2
Prior to use, wait at least 30 minutes for the SureClick® autoinjector and 45 minutes for the Pushtronex® system to naturally reach room temperature in the carton.1
Do not try to warm the prefilled cartridge by using a heat source, such as hot water or a microwave. If the prefilled cartridge has been warmed with a heat source, use a new onbody infusor and prefilled cartridge and call 1-844-REPATHA (844-737-2842) or visit www.Repatha.com.1
Using the SureClick® Autoinjector
Using the Pushtronex® System
References: 1. Repatha® (evolocumab) prescribing information, Amgen. 2. Dent R, Joshi R, Djedjos CS, et al. Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting. SpringerPlus. 2016:5;300. doi:10.1186/s40064-016-1892-3
Important Safety Information
Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.
Allergic Reactions: Hypersensitivity reactions (e.g. angioedema, rash, urticaria) have been reported in patients treated with Repatha®, including some that led to discontinuation of therapy. If signs or symptoms of serious allergic reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.
Adverse Reactions in Primary Hyperlipidemia (including HeFH): The most common adverse reactions (>5% of patients treated with Repatha® and occurring more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.
From a pool of the 52‐week trial and seven 12‐week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®‐treated and placebo‐treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising.
Allergic reactions occurred in 5.1% and 4.7% of Repatha®‐treated and placebo‐treated patients, respectively. The most common allergic reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).
Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and occurring more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).
Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new‐onset diabetes mellitus during the trial was 8.1% in patients assigned to Repatha® compared with 7.7% in those assigned to placebo.
Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.
Please see full Prescribing Information.